The American College of Rheumatology (ACR) updated its clinical guidance to include the reinitiation of treatment after the coronavirus disease 2019 (COVID-19) in adult patients with rheumatic diseases. The full report is published on the ACR website.

Updated ACR Recommendations for Management of Rheumatic Diseases in COVID-19

  • Reinitiating rheumatic disease treatment, including disease-modifying antirheumatic drugs, immunosuppressants, biologics, and Janus kinase inhibitors, may be considered within 7 to 14 days of symptom resolution in patients with uncomplicated COVID-19 infections (defined as mild or no pneumonia, with treatment in an ambulatory setting or by self-quarantine).
  • The ACR recommends that rheumatic disease treatment be reinitiated 10 to 17 days after patients have tested positive for severe acute respiratory syndrome coronavirus 2 and if they remain asymptomatic.
  • Rheumatologists and rheumatology professionals must make decisions on a case-by-case basis regarding the timing of reinitiation of rheumatic disease treatment in patients recovering from severe COVID-19-related illnesses.

Reference

American College of Rheumatology. COVID-19 clinical guidance for adult patients with rheumatic diseases. Updated July 13, 2020. Accessed July 27, 2020. https://www.rheumatology.org/Portals/0/Files/ACR-COVID-19-Clinical-Guidance-Summary-Patients-with-Rheumatic-Diseases.pdf